Navigation Links
Chimerix's Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
Date:12/13/2010

ietary PIM Conjugate Technology is being employed to improve the absorption and distribution profile of tenofovir, with the goal of increasing antiviral efficacy while decreasing potential toxicity. Chimerix is developing CMX157 for the treatment of patients who are refractory to or not sufficiently treated by existing HIV therapies.

About Chimerix

Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.

The company's lead candidate, CMX001, is in Phase 2 clinical studies in immunocompromised transplant and cancer patients for the treatment of life-threatening viruses, including cytomegalovirus and adenovirus.  Over 325 people have received CMX001 to date.  CMX001 has been well tolerated in all studies, with a growing body of evidence of the compound's antiviral activity in humans.  In Chimerix's ongoing placebo-controlled studies, CMX001 has been administered to more than 200 patients and healthy volunteers.  In addition, at the request of leading physicians at over 45 medical centers throughout the United States, Canada, Europe and Israel, CMX001 has been administered to more than 125 patients under investigator-held Emergency Investigational New Drug applications (EINDs) for the treatment of a wide range of infections caused by dsDNA viruses for which there are either no approved treatments or where patients have failed the available treatment.  To date, CMX001 has been used to treat patients with 12 different dsDNA viral infections across all five families of dsDNA viruses that affect humans. CMX001 is also being developed as a medical countermeasure in the event of a smallpox release.  Chimerix has received significant funding from the National Institutes of Allergy and Infectious Disease to develop CMX001 for smallpox.

Chimerix's second clinical-stage antiviral compound, C
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
2. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
3. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
4. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
5. BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
6. ViroDefense Inc Announces Selection of Poliovirus Antiviral Preclinical Candidate
7. Positive Phase I/II Data of IDX899 Confirm Potent Antiviral Activity and Favorable Safety Profile in Treatment-Naive HIV-Infected Patients
8. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
9. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
10. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
11. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... SAN DIEGO , Aug. 29, 2014 /PRNewswire/ ... an emerging biopharmaceutical company, announced today that Santosh ... will be leaving the Company, for personal reasons, ... the Chief Medical Officer of Aires Pharmaceuticals, which ... Vetticaden,s former responsibilities as the Company,s interim Chief ...
(Date:8/29/2014)... PLEASANTON, Calif. , Aug. 29, 2014 ... leader in device-based mechanical circulatory support therapies to save, ... be participating in the 2014 Morgan Stanley Global Healthcare ... F. Burbach , President and Chief Executive Officer, will ... p.m., Eastern Daylight Time (9:55 a.m., Pacific Daylight Time). ...
(Date:8/29/2014)... 2014 Research and Markets has ... Industry Report, 2014-2017" report to their offering. ... proportion of reimbursement for medical expenses, the Chinese orthopedic ... scale presenting a CAGR of 19.2% during 2009-2013. Trauma ... segments of orthopedic instruments in China ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2
(Date:8/31/2014)... 31, 2014 To make it easy ... they can trust, NutriGold is shipping complimentary samples of ... has been set up to make taking advantage of ... According to Priya Khan, Director of Research and Development ... one of our products, they are entrusting us with ...
(Date:8/31/2014)... Rockville, MD (PRWEB) August 31, 2014 ... electronic health records (EHR) software firm that focuses ... overall practice success found a congruent commitment with ... In Sports . , “We create an environment ... and effortlessly, allowing more time with patients,” says ...
(Date:8/31/2014)... Richmond, CA (PRWEB) August 31, 2014 ... program of the California State Library, celebrates 30 ... and their families. Since its inception, California’s Library ... a million Californians learn to read and write. ... this volunteer-based program, the state is launching a ...
(Date:8/31/2014)... Wine only protects against cardiovascular disease (CVD) in people ... Veritas (IVV) study presented at ESC Congress today by ... Taborsky said: "This is the first randomised trial comparing ... of atherosclerosis (1) in people at mild to moderate ... was only protective in people who exercised. Red and ...
(Date:8/30/2014)... A retrievable and repositionable transcatheter aortic valve is ... according to research presented at ESC Congress 2014 ... direct flow medical (DFM) transcatheter aortic valve has ... the potential to improve transcatheter aortic valve implantation ... , Dr Pyxaras said: "TAVI is well established ...
Breaking Medicine News(10 mins):Health News:Whole-food Supplement Samples Now Offered by NutriGold 2Health News:Whole-food Supplement Samples Now Offered by NutriGold 3Health News:Powerhouse EHR, Future Health, Announces Gold Sponsorship of POWERPlay in Sports National Tour 2Health News:Powerhouse EHR, Future Health, Announces Gold Sponsorship of POWERPlay in Sports National Tour 3Health News:Powerhouse EHR, Future Health, Announces Gold Sponsorship of POWERPlay in Sports National Tour 4Health News:California Library Literacy Services Celebrates 30th Anniversary 2Health News:California Library Literacy Services Celebrates 30th Anniversary 3Health News:Wine only protects against CVD in people who exercise 2Health News:Retrievable transcatheter aortic valve effective and safe in real world setting 2
... Reporter , MONDAY, May 28 (HealthDay News) -- Updated ... good news for those at risk of osteoporosis, but ... other chronic diseases. While estrogen-only and estrogen-plus-progestin formulations ... for stroke and other conditions including gallbladder disease, according ...
... study suggests that aspirin and other similar painkillers may ... CANCER , a peer-reviewed journal of the American ... may be added to the benefits of these commonly ... anti-inflammatory drugs, or NSAIDs, which include aspirin, ibuprofen, and ...
... Reporter , MONDAY, May 28 (HealthDay News) -- Sensory ... increasingly used by occupational therapists to treat children with ... organization says there isn,t much evidence that such therapies ... the potential of sensory therapies -- it,s a ripe ...
... -- Picnics, parades and cookouts are as much a part ... war veterans. But, before tucking into that leafy, green ... vegetables can become contaminated with harmful pathogens that cause food ... listeria and norovirus, according to the Academy of ...
... -- Boosting students, levels of physical education improves their ... followed more than 200 schoolchildren, starting from first through ... to an intervention group that received physical education five ... such as balance and coordination. The other children were ...
... , FRIDAY, May 25 (HealthDay News) -- People ... colitis, may be at increased risk for flare-ups when ... or mountain climbing, a new study suggests. This ... involves the small intestine) or ulcerative colitis (which typically ...
Cached Medicine News:Health News:HRT Update: Therapy May Reduce Fractures, Boost Some Risks 2Health News:HRT Update: Therapy May Reduce Fractures, Boost Some Risks 3Health News:Commonly used painkillers may protect against skin cancer 2Health News:Doubt Cast on Usefulness of 'Sensory' Therapies for Autism 2Health News:Doubt Cast on Usefulness of 'Sensory' Therapies for Autism 3Health News:Keep Food Safety in Mind This Memorial Day Weekend 2Health News:Travel to High Altitudes Tied to Crohn's, Colitis Flare-Ups 2
... Monitor (PCM) and Central Station provide an ... extends the cardiac cath or electrophysiology lab ... and/or EP procedures, providing both physiomonitoring parameters ... either standalone or on its own network. ...
For the critical care environment, telemetry, emergency room and other monitoring areas....
DS 7600 Central Station...
... Gemini Family of infusion pumps ... a collective series of administration ... line offers a wide variety ... sets, each featuring the patented ...
Medicine Products: